Equity Profile

KRYS

Krystal Biotech, Inc.

Health CareBiotechnology$9.7B

Mar18Mon

Pre-Earnings Brief

UpcomingQ2-2026Pre-Market9:00 AM EDT

Company Snapshot

Krystal Biotech, Inc. is a biotechnology company focused on developing gene therapies for skin diseases....

Key Metrics to Watch

Earnings Per Share (EPS)

EPS is a key indicator of the company's profitability and growth potential, which investors closely watch.

N/A

Revenue Growth

Revenue growth reflects the company's ability to expand its market presence and drive sales, essential for long-term success.

N/A

Wall Street expectations, options signals, track record, and call prep available with Pro.

KRYS Q2-2026 Earnings Preview

Context

Company Snapshot

Krystal Biotech, Inc. is a biotechnology company focused on developing gene therapies for skin diseases. With a market cap of $10 billion, its innovations could significantly impact the healthcare sector, particularly in treating rare genetic conditions.

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

75%

Avg EPS Surprise

+23.84%

Avg Stock Reaction

-1.56%

Last Quarter Recap

In Q1 2026, Krystal Biotech reported an EPS of $1.83, exceeding expectations by 26.21%. The stock reacted positively, gaining 7.86% the following day.

Management Promises & Guidance

Expectations

Wall Street Expectations

Overall, investors are optimistic about Krystal Biotech's upcoming earnings, especially after a strong performance last quarter. However, there is uncertainty due to the lack of specific guidance.

Bull Case

If Krystal Biotech continues to exceed EPS expectations, it could signal strong operational efficiency and market demand for its therapies, leading to further stock gains.

Bear Case

Conversely, if the company fails to meet expectations or provides weak guidance, it could lead to a significant drop in stock price, as seen in previous quarters.

Expectations

Two Questions That Matter

The print will turn on these two things.

What will the EPS be for Q2-2026?

Given the company's history of EPS surprises, this number will be crucial in determining market sentiment and stock movement.

How does management view revenue growth moving forward?

Any insights on revenue growth will help investors gauge the company's future performance and market position.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may be underestimating Krystal Biotech's potential for continued growth based on its recent performance and market position.

Supporting Evidence

The company has a strong track record of beating EPS estimates, with a 75% success rate over the last eight quarters.

Options are pricing a move of only 3.35%, while historical averages suggest a potential move of 7.71%.

Key Risk

If the EPS comes in above $2.00, it could significantly shift market sentiment and expectations.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

The market is debating whether Krystal Biotech can maintain its growth momentum after a strong Q1 performance.

Bull Confirmed If

An EPS of $2.00 or higher would confirm strong operational performance and investor confidence.

Bear Confirmed If

An EPS below $1.50 would raise concerns about the company's growth trajectory and market demand.

Pre-Earnings Positioning

Options Market

Implied Move

±3.35%

Historical Avg

±7.7%

Pricing cheap

The options market is pricing in a modest move of about 3.35%, suggesting that traders expect limited volatility around the earnings announcement.

Options are pricing ±3.3% while KRYS has averaged ±7.7% over the last 8 prints — setup is pricing cheap.

Detail

ATM IV

0.4%

30d HV

38.7%

Calls (1K)P/C Ratio: 0.13Puts (3K)

Edge

Historical Setup Match

Cross-company pattern from 30 similar setups.

Prior-quarter beat + options pricing cheap in Health Care

n=30

Fade rate: 13 of 29 (45%)

This setup has occurred 30 times across Health Care in the last 2 years. 13 of 29 faded and 16 held — no strong directional bias after the initial reaction. The average absolute 1-day move is 5.5%, with a raw directional average of +2.9% (modestly positive historical bias).

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Krystal Biotech beats expectations, history suggests a potential stock increase of around 2.6%, confirming strong operational strength.

In-Line / Cautious

If results are in line with expectations, the stock may see muted movement as investors await further guidance.

Miss

A miss could lead to a decline of about 14.05%, reflecting investor disappointment and concerns about future growth.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any updates on new product developments or pipeline advancements.
2Management's commentary on market conditions and competitive landscape.
3Insights into customer demand and adoption rates for their therapies.
4Guidance on revenue expectations for the next quarter.
5Any strategic partnerships or collaborations that may impact growth.

See the full picture

AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.

No charge today · Auto-bills $8/mo after 7 days · Cancel anytime

More Earnings This Week

5 Reports

Gen Digital Inc.

Company Snapshot

Krystal Biotech, Inc. is a biotechnology company focused on developing gene therapies for skin diseases....

Key Metrics to Watch

Earnings Per Share (EPS)

EPS is a key indicator of the company's profitability and growth potential, which investors closely watch.

N/A

Revenue Growth

Revenue growth reflects the company's ability to expand its market presence and drive sales, essential for long-term success.

N/A

Wall Street expectations, options signals, track record, and call prep available with Pro.

KRYS Q2-2026 Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

75%

Avg EPS Surprise

+23.84%

Avg Stock Reaction

-1.56%

Last Quarter Recap

In Q1 2026, Krystal Biotech reported an EPS of $1.83, exceeding expectations by 26.21%. The stock reacted positively, gaining 7.86% the following day.

Management Promises & Guidance

Expectations

Wall Street Expectations

Overall, investors are optimistic about Krystal Biotech's upcoming earnings, especially after a strong performance last quarter. However, there is uncertainty due to the lack of specific guidance.

Bull Case

If Krystal Biotech continues to exceed EPS expectations, it could signal strong operational efficiency and market demand for its therapies, leading to further stock gains.

Bear Case

Conversely, if the company fails to meet expectations or provides weak guidance, it could lead to a significant drop in stock price, as seen in previous quarters.

Expectations

Two Questions That Matter

The print will turn on these two things.

What will the EPS be for Q2-2026?

Given the company's history of EPS surprises, this number will be crucial in determining market sentiment and stock movement.

How does management view revenue growth moving forward?

Any insights on revenue growth will help investors gauge the company's future performance and market position.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may be underestimating Krystal Biotech's potential for continued growth based on its recent performance and market position.

Supporting Evidence

The company has a strong track record of beating EPS estimates, with a 75% success rate over the last eight quarters.

Options are pricing a move of only 3.35%, while historical averages suggest a potential move of 7.71%.

Key Risk

If the EPS comes in above $2.00, it could significantly shift market sentiment and expectations.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

The market is debating whether Krystal Biotech can maintain its growth momentum after a strong Q1 performance.

Bull Confirmed If

An EPS of $2.00 or higher would confirm strong operational performance and investor confidence.

Bear Confirmed If

An EPS below $1.50 would raise concerns about the company's growth trajectory and market demand.

Pre-Earnings Positioning

Options Market

Implied Move

±3.35%

Historical Avg

±7.7%

Pricing cheap

The options market is pricing in a modest move of about 3.35%, suggesting that traders expect limited volatility around the earnings announcement.

Options are pricing ±3.3% while KRYS has averaged ±7.7% over the last 8 prints — setup is pricing cheap.

Detail

ATM IV

0.4%

30d HV

38.7%

Calls (1K)P/C Ratio: 0.13Puts (3K)

Edge

Historical Setup Match

Cross-company pattern from 30 similar setups.

Prior-quarter beat + options pricing cheap in Health Care

n=30

Fade rate: 13 of 29 (45%)

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Krystal Biotech beats expectations, history suggests a potential stock increase of around 2.6%, confirming strong operational strength.

In-Line / Cautious

If results are in line with expectations, the stock may see muted movement as investors await further guidance.

Miss

A miss could lead to a decline of about 14.05%, reflecting investor disappointment and concerns about future growth.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any updates on new product developments or pipeline advancements.
2Management's commentary on market conditions and competitive landscape.
3Insights into customer demand and adoption rates for their therapies.
4Guidance on revenue expectations for the next quarter.
5Any strategic partnerships or collaborations that may impact growth.